Slide 1: Results Q1 2025 Faes Farma
dF FAES FARMA RESULTS Q1 2025 FAES FARMA
Slide 2: Index
INDEX 1/ Highlights and key figures 2/ Sales evolution Q1 2025 3/ Financial results, Outlook and Q&A 2
Slide 3: Highlights and key figures
Highlights and key figures 3
Slide 4: Highlights
HIGHLIGHTS AND KEY FIGURES Q1 2025 Highlights / Total income +9.7%, in the high range of our guidance, driven by growth in the three strategic molecules +14%. BUSINESS / Pharma income +8%, with the LATAM markets (+19%) and Licences (+12%) being the main growth drivers. / Adjusted EBITDA +3% excludin
Slide 5: Key figures Q1 2025
HIGHLIGHTS AND KEY FIGURES Q1 2025 Key figures Q1 2025 Income EBITDA 153.0 M€ 39.3 M€ +9.7% -4.1% Income Top 3 molecules Adjusted EBITDA* 66.7 M€ 42.2 M€ +14.5% +3.0% Pharma income Net Profit 136.3 M€ 28.4 M€ +8% -6.8% *EBITDA exluiding extraordinary costs Derio 5
Slide 6: Sales evolution Q1 2025
Sales evolution Q1 2025 6
Slide 7: Growth in all areas of the Group
SALES EVOLUTION Q1 2025 Growth in all areas of the Group Led by the strong performance of the three strategic molecules Iincome by porfolio line Income by portfolio line Q1 2025 Q1 2024 % 11% Animal nutrition and health Pharma 136.3 126.1 8% 44% Pharma top 3 molecules 66.7 58.3 14% Top 3 molecules R
Slide 8: Highlights of the main molecules
SALES EVOLUTION Q1 2025 Highlights of the main molecules Very positive evolution with outstanding performance in both direct sales and Licences Bilastine 44.3 M€ Good performance during the quarter with growth of +15% in which the main driver was the evolution of the international subsidiaries accom
Slide 9: All business areas trending positively
SALES EVOLUTION Q1 2025 All business areas trending positively Income by business area Income by business area Q1 2025 Q1 2024 % 11% Animal nutrition and health Pharma 136.3 126.1 8% Pharma Spain 58.8 55.6 5% 38% Pharma International (without licenses) 37.5 34.7 8% Pharma Iberia Pharma Licenses 39.5
Slide 10: Pharma business, solid growth in all key areas
SALES EVOLUTION Q1 2025 Pharma business, solid growth in all 3 key areas Pharma’s income evolution in M€ Total Pharma income: 136.3 M€ +8% Iberia* +6% /01 55.6 58.8 IBERIA +6% Led by the whole of Pharma Spain +7%, whose growth in both prescription and healthcare offset part of the slowdown in Portug
Slide 11: Pharma Iberia, the different channels are growing in line with expectations
SALES EVOLUTION Q1 2025 Pharma Pharma Iberia, the different channels are growing in line with expectations Iberia income: 58.8 M€ +6% Income evolution of Pharma Iberia in M€ /01 Spain SPAIN +7% +7% 49.8 Prescription sales increased by +7% with positive evolution of all 46.6 strategic products, espec
Slide 12: Pharma International, LATAM as a clear growth engine
SALES EVOLUTION Q1 2025 Pharma Pharma International, LATAM as a clear growth engine International income: 37.5M€, +8% Income evolution of Pharma International in M€ /01 LATAM LATAM +19% +19% 24.5 Colombia +51% strong growth supported by a significant increase in 20.6 the commercial team. Ecuador +36
Slide 13: Licences
SALES EVOLUTION Q1 2025 Pharma Licences Licences income: 39.5M€ +12% Income evolution of Licences in M€ /01 BILASTINE +5% Bilastine Growth in new markets (Australia and China) and very positive 30.1 28.6 +5% developments in existing markets (mainly Eastern Europe and South East Asia). Brazil, one of
Slide 14: Animal nutrition and health
SALES EVOLUTION Q1 2025 Farm Animal nutrition and health Income evolution FARM Faes in M€ FARM Faes income: 16.7M€ +29% /01 +29% 16.7 12.9 Significant sales growth despite the fact that, at a sector level, the domestic pork market continues to be affected by PRRS (porcine reproductive and respirator
Slide 15: Financial Results, Outlook and Q&A
3/ Financial Results, Outlook and Q&A 15
Slide 16: P&L Highlights Q1 2025
FINANCIAL RESULTS AND OUTLOOK P&L Results Thousand € Q1 2025 Q1 2024 %change Ordinary income (sales) 145,565 131,133 11,0% Highlights Q1 2025 Other operating income 7,434 7,892 -5,8% Work carried out for the company for its assets 0 406 - /01 – Income Tota Income 152,999 139,431 9,7% Double-digit gr
Slide 17: Outlook 2025 vs Q1 2025
FINANCIAL RESULTS & OUTLOOK Outlook 2025 vs Q1 2025 Income 2025 Income Q1 2025 +8/10% +9,7% EBITDA 2025 EBITDA Q1 2025 -6/-9% -4,1% EBITDA adjusted* 2025 EBITDA adjusted* Q1 2025 +3/5% +3% *2025 Excl. Derio one off cost 17
Slide 18: Q&A
Q&A
Slide 19: Disclaimer
DISCLAIMER This presentation has been prepared and published by Faes Pharma Group for information purposes only. This presentation does not constitute a prospectus or an offer or recommendation to invest. This presentation does not constitute a commitment to subscribe, an offer of financing or an of
Slide 20: Appendix
Appendix INCOME PHARMA IBERIA INCOME INTERNACIONAL (without licences) INCOME LICENCES INCOME FARM FAES Q1 2025 Q1 2024* %var Q1 2025 Q1 2024* %var Q1 2025 Q1 2024* %var Q1 2025 Q1 2024* %var Pharma Spain 49.8 46.6 7% International 37.5 34.7 8% Licences 39.5 35.1 12% Animal health and nutrition 16.7